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Very long-chain acyl-coA dehydrogenase (VLCAD) is the 
rate-limiting step in mitochondrial fatty acid oxidation. 
VLCAD-deficient mice and patients clinical symptoms 
stem from not only an energy deficiency but also long-
chain metabolite accumulations. VLCAD-deficient mice 
were treated systemically with 1 × 1012 vector genomes 
of recombinant adeno-associated virus 9 (rAAV9)-VLCAD. 
Biochemical correction was observed in vector-treated 
mice beginning 2 weeks postinjection, as characterized 
by a significant drop in long-chain fatty acyl accumulates 
in whole blood after an overnight fast. Changes persisted 
through the termination point around 20 weeks postin-
jection. Magnetic resonance spectroscopy (MRS) and 
tandem mass spectrometry (MS/MS) revealed normaliza-
tion of intramuscular lipids in treated animals. Correction 
was not observed in liver tissue extracts, but cardiac mus-
cle extracts showed significant reduction of long-chain 
metabolites. Disease-specific phenotypes were charac-
terized, including thermoregulation and maintenance of 
euglycemia after a fasting cold challenge. Internal body 
temperatures of untreated VLCAD−/− mice dropped below 
20 °C and the mice became lethargic, requiring eutha-
nasia. In contrast, all rAAV9-treated VLCAD−/− mice and 
the wild-type controls maintained body temperatures. 
rAAV9-treated VLCAD−/− mice maintained euglycemia, 
whereas untreated VLCAD−/− mice suffered hypoglyce-
mia following a fasting cold challenge. These promising 
results suggest rAAV9 gene therapy as a potential treat-
ment for VLCAD deficiency in humans.
Received 15 December 2011; accepted 6 February 2012; advance online 
publication 6 March 2012. doi:10.1038/mt.2012.39
IntroductIon
Very long-chain acyl-coA dehydrogenase (VLCAD) deficiency is 
the most common disorder of long-chain fatty acid metabolism, 
with a regional incidence of 1 in 30,000 births, and second in 
frequency only to medium-chain acyl-coA dehydrogenase defi-
ciency among disorders of fatty acid oxidation.1,2 Characterized 
by the most severe phenotype within the acyl-coA dehydrogenase 
deficiency family, patients generally present with one of three 
distinct clinical phenotypes. Of these three phenotypes the early 
onset presentation during infancy is the most severe, presenting 
with cardiomyopathy and hepatopathy and are often fatal.3 A less 
severe hepatic phenotype presenting with recurrent hypoketotic 
hypoglycemia, also occurs in infancy to early childhood. The third 
phenotype is a mild, myopathic form presenting in adolescence or 
adulthood with muscle weakness, myalgia and myoglobinuria.4,5
VLCAD is responsible for catabolism of long-chain fatty acids, 
with highest specificity for carbon lengths C14–C18, as part of the 
mitochondrial β-oxidation spiral. It is the rate-limiting enzyme in 
the process, causing an energy deficiency as well as accumulations 
of long-chain fatty acids. β-Oxidation is an important source of 
energy for liver and muscle, especially cardiac muscle. The disease 
is associated with a lack of energy caused by the inability to break-
down long-chain fatty acids but the accumulates of these long-
chain fatty acids can also be detrimental.6,7 The amassments of 
these metabolites are exploited for diagnostic purposes as part of 
the newborn screening by analyzing for acyl carnitine metabolite 
accumulations in the blood by tandem mass spectrometry (MS/
MS). Although newborn screening has reduced mortality, the cur-
rent treatment is limited to fasting avoidance, and supplementa-
tion of medium-chain triglycerides, which remains controversial 
since supplementation of medium-chain triglycerides in excess 
of the immediate caloric demand will induce the production of 
longer chain fatty acids for storage as triglycerides.8 These in turn 
will add to the total load of longer chain fatty acids, which can-
not be subsequently metabolized when caloric restriction occurs. 
Therefore, VLCAD deficiency is a candidate for gene therapy 
because of its limited treatment options as well as its potentially 
fatal phenotype.
We have previously shown biochemical correction of short-
chain acyl-coA dehydrogenase deficiency by targeting muscle 
with recombinant adeno-associated virus 1 (rAAV1) and rAAV2, 
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and liver with rAAV8 as well as long-chain acyl-coA dehydro-
genase deficiency by targeting the muscle with rAAV1.9–11 New 
AAV serotypes, such as AAV9, have improved expression and 
wider transduction profiles.12,13 Merritt and colleagues14 showed 
limited biochemical correction of VLCAD deficiency using sys-
temic injections with AAV8. Here, we present the first evidence of 
a genetic therapy that systemically targets major tissues involved 
in β-oxidation, has long-term expression and corrects several dis-
ease-specific phenotypes in a VLCAD-deficient mouse model.
results
differential expression, transduction, and tissue 
distribution of rAAV9-VlcAd
To assess the therapeutic benefit of rAAV9-VLCAD comple-
mentary DNA delivery, 6–8-week-old VLCAD−/− or VLCAD+/+ 
littermate controls were injected into the tail vein with either 
rAAV9-CBA-VLCAD (1 × 1012 vector genomes) as a therapeu-
tic agent or rAAV9-CBA green fluorescent protein or phosphate-
buffered saline (PBS) as controls. Quantitative real-time PCR was 
performed on genomic DNA (gDNA) isolated from multiple tis-
sues at 22–26 weeks postinjection to determine tissue distribution 
of vector genomes (Figure 1a). All tissues were negative for vector 
genomes in PBS VLCAD−/− or PBS VLCAD+/+ controls. In mice 
injected with rAAV9-VLCAD, the highest vector genome concen-
tration in tissues associated with fatty acid oxidation was observed 
in the liver, followed by heart, skeletal muscle, and brown fat. 
Expression is shown by human VLCAD antibody staining of the 
liver, heart, tibialis anterior muscle, and brown fat (Figure 1b–i). 
Also vector genomes were found present in tissues not associ-
ated with fatty acid oxidation including gonads, lung, spleen, and 
lymph nodes (Figure 1a). Although transduction of the liver had 
the highest transduction among the tissues, liver expression was 
not widespread, with numerous cells expressing VLCAD at high 
levels while others did not express VLCAD (Figure 1c). Expression 
of VLCAD in the heart and tibialis anterior was widespread 
(Figure 1e,g). Interestingly, transduction and expression were seen 
in the brown fat (Figure 1h,i). Liver and muscle were also stained 
with hematoxylin and eosin and scored by a blinded pathologist 
for inflammation (Supplementary Figure S1). Some inflamma-
tion was seen across all groups and no significant difference was 
seen in inflammation between PBS control and AAV9-VLCAD 
treated VLCAD−/− in the liver. No inflammation was seen in any 
group within the muscle. Taken together, these results indicate 
that rAAV9-VLCAD vectors were able to sufficiently transduce 
and express for over 6 months in vital organs, which rely on fatty 
acid oxidation.
correction of acyl carnitine accumulates in the blood
Because VLCAD-deficient patients have a greater magnitude of 
accumulation of long-chain acyl carnitines in the blood, it was 
essential to demonstrate biochemical correction of whole blood 
by measuring acyl carnitine accumulates by electrospray MS/MS. 
Before treatment, and on days 14, 42, and 140 postinjection, mice 
were subjected to a 24-hour fast followed by whole blood col-
lection. Metabolic stress such as fasting was required to observe 
optimal response. Large accumulations of long-chain metabo-
lites were found in VLCAD−/− PBS controls and reductions of the 
levels of C14, C16:1, C16, C18:2, C18:1, and C18 were seen 14 
days postinjection in rAAV9-treated VLCAD−/− animals when 
compared to VLCAD−/− PBS controls (Figure 2a). There were no 
significant differences between controls, AAV9-green fluorescent 
protein or PBS, so PBS was used as a control for subsequent exper-
iments (Supplementary Figure S2a–c). It was noted that reduc-
tions in blood acyl carnitines were observed across all groups 
between the first and second 24-hour fasting time points, regard-
less of treatment, age, or if mice remained uninjected (Figure 3a 
and Supplementary Figure S3a–f), a phenomena that is also 
observed in our medium-chain acyl-coA dehydrogenase defi-
ciency mice. Significant reductions in levels of C16, C18:1, C18 
(Figure 2b–d, P < 0.0006; Supplementary Figure S2a–c) in whole 
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Figure 1 transduction and expression of rAAV9-VlcAd. (a) Quantitative-PCR for vector genomes. Means of three separate assays ± SEM are 
shown for each organ. n = 7 VLCAD−/− phosphate-buffered saline (PBS) control, 6 VLCAD−/− rAAV9-VLCAD treated and VLCAD+/+ PBS control. Only 
VLCAD−/− rAAV9 treated are shown, as PBS controls were all negative. Error bars are SEM. (b–i) Representative images of very long-chain acyl-coA 
dehydrogenase (VLCAD) antibody staining in VLCAD−/− mice, 21–26 weeks postinjection, 5× magnification. (b) Liver PBS control. (c) Liver, rAAV9-
VLCAD treated. (d) Heart, PBS control. (e) Heart, rAAV9-VLCAD treated. (f) Tibialis anterior (TA) muscle, PBS control. (g) TA, rAAV9-VLCAD treated. 
(h) Brown fat, PBS control. (i) Brown fat, rAAV9-VLCAD treated.
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blood persisted for over 140 days postinjection of rAAV9-VLCAD 
when compared to the PBS controls. These reductions, which were 
observed out to 140 days postinjection, infer biochemical correc-
tion of the whole blood.
tissue correction in vivo and ex vivo
Biochemical correction within the liver tissue itself was assessed 
by an in vivo and ex vivo approach. Using single voxel proton mag-
netic resonance spectroscopy (1H-MRS), lipid accumulations in 
the liver were measured in live animals 17 weeks postinjection. 
Figure 3a shows representative liver spectra from VLCAD−/− PBS 
control, VLCAD−/− AAV9-treated and VLCAD+/+ PBS control 
mice. A measure of total lipid, the ratio of the area under the lipid 
peak divided by the area under the water peak, as an internal con-
trol is shown in Figure 3b. No significant differences were seen 
in accumulations measured by MRS between the VLCAD−/− and 
VLCAD+/+ or rAAV9-treated groups. Ex vivo acyl carnitine accu-
mulations were measured by MS/MS of the liver tissue. Significant 
differences in reduction of C16, C18:2, C18:1, and C18 were 
observed between the VLCAD−/− PBS control and VLCAD+/+ mice 
(Figure 3c). Unexpectedly, reductions were not seen in the liver 
of the VLCAD−/− rAAV9-treated animals, despite the significant 
reductions seen in whole blood.
Analogously, we assessed biochemical correction in the muscle 
tissue employing the same in vivo/ex vivo approach. Figure 4a is 
an magnetic resonance image of a representative muscle, with the 
box indicating the location within the muscle where the 1H-MRS 
spectrum was taken. Representative spectra from VLCAD−/− PBS 
control, VLCAD−/− rAAV9-treated and VLCAD+/+ PBS control 
mice are shown in Figure 4b. The ratio of the area under the lipid 
peak was divided by the area under the taurine, trimethyl ammo-
nium, and creatine total peak, as the internal control for muscle. 
Comparison of VLCAD−/− PBS control, VLCAD−/− rAAV9-treated, 
and VLCAD+/+ PBS control mice, lipid peak ratios are shown in 
Figure 4c. The VLCAD−/− PBS control mice had accumulation of 
lipids within the muscle whereas the VLCAD−/− rAAV9 treated 
exhibited reduced lipid content similar to wild-type mice. Acyl 
carnitine accumulations were observed from ex vivo tissue by 
MS/MS for both the extensor digitorum longus, primarily com-
posed of fast twitch muscle, and the soleus, primarily composed of 
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Figure 2 reduction of acyl carnitines in rAAV9-very long-chain acyl-coA dehydrogenase (VlcAd)-treated mice. All animals were fasted 24 
hours before bleeding. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (a) Quantities of acyl carnitine species as assessed by mass spectrometry of 
whole blood day 14 postinjection. n = 7 untreated VLCAD−/− controls, n = 6 rAAV9-treated VLCAD−/− mice; and n = 6 in wild-type controls. Error bars 
are SEM. P values are as follows: C14 P = 0.002, C16:1 P ≤ 0.0001 C16 P = 0.0008 C18:2 P = 0.005, C18:1 P = 0.005, C18 P = 0.04. (b–d) Untreated 
VLCAD−/− controls day 0 and 14 n = 11; day 6 n = 3; D140 n = 7. rAAV9-treated VLCAD−/− mice day 0 and 14 n = 11; day 6 n = 5; D140 n = 6. Wild-
type control mice day 0, 14 n = 11; day 6 n = 5; D140 n = 6. (b) Mass spectrometric quantification of C16 in the whole blood over time. Error bars are 
SEM. A two-way analysis of variance (ANOVA) was performed on data from day 14–day 140 with P = 0.0006. (c) Mass spectrometric quantification 
of C18:1 over time. Error bars are SEM. A two-way ANOVA was performed on data from day 14–day 140 with P = 0.0003. (d) Mass spectrometric 
quantification of C18 over time. Error bars are SEM. A two-way ANOVA was performed on data from day 14–day 140 with P = 0.0014.
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slow twitch fibers. Reductions of long-chain accumulations were 
observed in both the extensor digitorum longus (Figure 4d) and 
soleus (Figure 4e) in the rAAV9-treated animals. Furthermore, 
expression of VLCAD in the skeletal muscle reduced accumula-
tions of acyl carnitines within the tissue.
Cardiomyopathy can be a presenting symptom in patients 
with VLCAD deficiency.15,16 Since expression was widespread in 
the heart (Figure 1e), a question remained if biochemical correc-
tion of the cardiac tissue had occurred. Cardiac tissue was ana-
lyzed by MS/MS of acyl carnitines extracted from ex vivo tissue. 
Acyl carnitines in cardiac muscle were at or below wild-type levels 
in rAAV9-treated mice whereas VLCAD−/− PBS controls had large 
accumulations (Figure 5). Expression of VLCAD in cardiac mus-
cle, facilitated by rAAV9, was able to correct VLCAD−/− animals to 
wild-type levels of acyl carnitines in the cardiac tissue instead of 
large accumulations seen in VLCAD−/− animals.
disease-specific phenotypic correction of VlcAd 
deficiency
Cold can induce metabolic derangement in VLCAD deficiency 
patients, as production of heat requires fatty acid oxidation 
especially after dietary fat stores have been used up.17 VLCAD-
deficient mice are also unable to maintain body temperatures dur-
ing a cold challenge, and it has been shown to be fatal especially 
when combined with fasting.18 To assay for disease-specific phe-
notypic correction, a cold fast challenge was utilized, in which the 
mice are fasted for 18 hours followed by a cold challenge in a 4 °C 
room. During the challenge, a humane sacrifice was performed 
for animals with a body temperature below 20 °C as determined 
by Institutional Animal Care and Use Committee (IACUC). 
In Figure 6a, the VLCAD−/− AAV9-treated and wild-type ani-
mals were able to maintain average body temperatures of 26.15 
and 26.4 °C, respectively for 150 minutes. However, PBS control 
VLCAD−/− animals were unable to maintain body temperatures 
above 20 °C, with two animals being euthanized at 110 minutes 
and the remaining two animals at 130 minutes. To summarize, 
by 150 minutes into the cold challenge all of the PBS control 
VLCAD−/− animals had internal temperatures that dropped below 
the humane sacrifice point, whereas all the VLCAD−/− AAV9-
treated, and wild-type animals survived (Figure 6b). Lethargy 
and hypotonia are often a presenting symptom when VLCAD-
deficient patients are undergoing a period of metabolic crisis.7 
PBS control VLCAD-deficient animals became lethargic and 
hypotonic during the cold fast challenge (Supplementary Video 
S1). In contrast, rAAV9-treated animals as well as the wild-type 
animals did not display lethargy and hypotonia as can be appreci-
ated (Supplementary Videos S2 and S3).
Hypoketotic hypoglycemia is a primary presenting symptom 
for in VLCAD-deficient patients. Blood glucose levels were com-
pared in all three strains, in fed, fasted, and cold challenge state. 
There were no significant differences between any of the groups 
at the fed levels, however, blood glucose levels were significantly 
reduced following both at fasting and cold challenge in the PBS 
control VLCAD-deficient animals when compared to the wild-
type mice (Figure 6c). In contrast, the rAAV9-VLCAD-treated 
animals fully corrected glucose levels to that of wild-type under 
all conditions. One wild-type mouse had blood glucose levels of 
278 mg/dl, which drove the average up in the wild-type after the 
cold fast challenge. However, blood glucose levels after the cold 
fast challenge, were not significantly different from the VLCAD−/− 
rAAV9-treated and the wild-type mice, whereas VLCAD−/− ani-
mals blood glucose levels were significantly reduced.
dIscussIon
Phenotypic correction of multiple disease-specific phenotypes, 
including blood acyl carnitines, thermoregulation, resistance to 
lethargy, and blood glucose maintenance was shown here using of 
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Figure 3 Biochemical analysis of acyl carnitines in the liver in vivo and 
ex vivo. (a) Representative spectra from magnetic resonance  spectrometry 
of liver in vivo. 17–18 weeks postinjection. (b) Quantification of the ratio 
of the area of the lipid peak/area of the water peak. Error bars are SEM. 
n = 3. (c) Mass spectrometric analysis of liver tissue ex vivo, 21–25 weeks 
postinjection; n = 7 untreated VLCAD−/− controls, n = 6 rAAV9-treated 
VLCAD−/− and wild-type controls. Error bars are SEM. Samples were ana-
lyzed in triplicate. VLCAD, very long-chain acyl-coA dehydrogenase.
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rAAV9-mediated gene therapy in a mouse model of VLCAD defi-
ciency. Unlike the previous work by Merritt and colleagues,14 we 
were able to show long-term expression of VLCAD in all targeted 
tissues including liver, brown fat, cardiac and skeletal muscle. 
The difference in long-term expression could have been due to 
the use of the CBA expression cassette over the CMV promoter, 
the latter of which is known to be inactivated in the liver in the 
absence of nuclear factor-kβ.19 Also the use of rAAV9, which has 
been shown previously to target tissues involved in fatty acid oxi-
dation after systemic delivery, could have allowed for better sys-
temic correction. A clinically translatable noninvasive technique, 
MRS, was employed to measure correction within the muscle and 
liver. Results from the MRS were confirmed with MS/MS of the 
tissues. Within the liver tissue, accumulates were mildly reduced 
as detected by MRS and MS/MS but not to the extent seen in other 
tissues such as skeletal muscle. No previous work concerning cor-
rection of disorders of fatty acid oxidation have employed MS/
MS of tissue samples to measure accumulations of acyl carniti-
nes within tissues themselves. Correction of short-chain acyl-coA 
dehydrogenase using rAAV8 showed reduction of liver accumu-
lated by MRS but this was a targeted approach injecting into the 
portal vein.10 The VLCAD staining pattern in the liver is differ-
ent from that within the cardiac and skeletal muscle where it is 
widespread but at a low level of expression. Within the liver, it 
appeared that certain cells were expressing VLCAD at very high 
levels, while other cells were not expressing at all. However with-
out efficient targeting of the liver, reduction of accumulates in 
the blood as well as maintenance of blood glucose levels would 
not be expected. This expression pattern may cause the correc-
tion discrepancy between whole liver extract accumulations and 
the impact of the liver on reducing whole blood accumulates and 
maintaining blood glucose levels. This phenomenon has been pre-
viously reported using rAAV8.20
Expression of VLCAD in brown fat after systemic injection 
is also novel. To our knowledge, there have been no reports that 
have shown transduction of brown adipose tissue and only two 
reports attempting to target white adipose tissue. Both reports 
used AAV1 and required an enhancing agent in order to get 
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Figure 4 reduction of lipids in the muscle of corrected mice in vivo and ex vivo. *P < 0.05, **P < 0.01, ***P < 0.001. (a) Magnetic resonance image 
(MRI) of hindlimb muscle 12–14 weeks postinjection. (b) Representative spectra from MRS of muscle in vivo. (c) Quantification of the ratio of the area of 
the lipid peak/area of the taurine–creatine peak. n = 7 untreated VLCAD−/− controls, n = 6 rAAV9-treated VLCAD−/− animals and wild-type controls. Error 
bars are SEM. (d) Mass spectrometry of extensor digitorum longus (EDL) ex vivo 21–25 weeks postinjection. n = 7 untreated VLCAD−/− controls, n = 6 
AAV9-treated VLCAD−/− and wild-type controls. Error bars are SEM. Differences were as follows: C16 P = 0.09, C18:2 P = 0.06 C18:1 P = 0.06 C18 P = 
0.05. Samples were run in triplicate. (e) Mass spectrometry of soleus (SOL) ex vivo 21–25 weeks postinjection. n = 7 untreated VLCAD−/− controls, 6 rAAV9 
VLCAD−/− and wild-type controls. Error bars are SEM. Statistics were as follows: C16 NS, C18:2 P = 0.001, C18:1 P = NS, C18p = NS.
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efficient transduction.21,22 In this report, we were primarily con-
cerned with brown adipose tissue because of its important role in 
thermogenesis. Brown fat differs from white adipose tissue in that 
it is highly vascularized, which gives rAAV9 easy access to brown 
adipose tissue when given systemically however that does not nec-
essarily imply transduction or expression. Transduction was also 
seen in other tissues including the lung, lymph nodes, spleen and 
gonads. Detargeting strategies such as capsid mutations and tissue 
specific promoters and microRNAs may be employed to minimize 
transduction and expression in unwanted tissues, if this ultimately 
proves to be necessary.
The pronounced in ability of AAV9-treated VLCAD−/− mice 
to thermoregulate body temperature in a cold environment com-
pared to the untreated mice clearly demonstrates correction 
of the cold sensitive phenotype. The role brown fat plays in the 
phenotypic correction of these mice has yet to be determined; 
however, it is suspected that brown fat is not solely responsible 
for temperature maintenance during the cold fast challenge. 
Brown fat plays an important role in nonshivering thermogen-
esis by expressing UCP-1 protein, which allows uncoupling of 
oxidative phosphorylation and the production of heat. Brown 
fat has a vital role in thermogenesis in newborns, and is pres-
ent and functional in adult humans although to a lesser extent.23 
Work by Skilling and colleagues,24 suggests that brown fat does 
not play as strong of a role in VLCAD-deficient sensitivity to cold 
as it does in shorter chain deficient animals such as short-chain 
acyl-coA dehydrogenase. They suggest that rapid consumption 
of glycogen in the liver and muscle as well as impaired ability 
to shiver and decreased cardiac function is responsible for cold 
sensitivity.24 Unlike other disorders of fatty acid oxidation no 
energy can be produced by fatty acid oxidation, as VLCAD is the 
rate-limiting enzyme. Exil and collegues,25 report that VLCAD-
deficient animals succumb to bradycardia, during the cold fast 
challenge. Therefore, both shivering and nonshivering thermo-
genesis may play a role in the defect in thermoregulation in these 
mice. rAAV-mediated expression of VLCAD in liver, allowing the 
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Figure 6 Phenotypic correction with rAAV9-very long-chain acyl-coA 
dehydrogenase (VlcAd)-treated mice after cold fast challenge. *P < 
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and NS = not significant. 
(a) Core body temperature of mice undergoing cold fast challenge, tem-
peratures were recorded every 20 minutes by rectal thermometer. Mice 
were humanely sacrificed if body temperatures dropped below 20 °C, 
n = 4. Error bars are SEM. P = value by two-way analysis of variance 
(ANOVA) P ≤ 0.0001. (b) Survival of cold fast challenge. (c) Blood glu-
cose levels during fed, fasted and fasted plus cold challenge conditions, 
n = 4. Error bars are SEM. No significant difference at fed state between 
all groups or between rAAV9-treated animals and wild-type under any 
condition, P = 0.005.
8
6
4
2
0
N
an
om
ol
e/
g
C1
6
C1
8:2
C1
8:1 C1
8
Acylcarnitine
VLCAD−/− PBS control
VLCAD−/− AAV9-VLCAD treated
VLCAD+/+ PBS treated
**
**
**
**
Figure 5 reduction of acyl carnitines in the heart. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001. Mass spectrometry of heart tissue ex 
vivo 21–25 weeks postinjection. n = 7 untreated VLCAD−/− controls, n = 
6 AAV9 VCLAD−/− and wild-type controls. Error bars are SEM. Statistics 
were as follows: C16 P = 0.003 C18:2 P = 0.005 C18:1 P = 0.004 C18 
P = 0.005. VLCAD, very long-chain acyl-coA dehydrogenase.
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animal to produce ketones which can go on to produce energy 
in other tissues may have a larger impact on thermogenesis than 
expression of VLCAD in the brown fat as VLCAD-deficient mice 
retain 80% residual activity in the brown fat.24 Also rAAV-medi-
ated expression of VLCAD in the muscle may allow for heat pro-
duction through shivering. Correction of multiple tissues may be 
necessary in order to see correction of this phenotype.
Current standard of care for VLCAD patients is primarily 
dietary, limiting long-chain fatty acids and supplementing with 
medium chains as well as avoidance of fasting. Studies have shown 
effectiveness, especially when administered prior to exercise.26,27 
However, even with screening and treatment, ~10–20% of patients 
suffer episodic rhabdomyolysis.28 Supplementation of medium-
chain triglycerides has come under question since patients can 
suffer myopathic symptoms despite treatment and studies in 
VLCAD-deficient mice have shown muscle phenotypes after exer-
cise on fat-reduced carbohydrate-enriched diets.29 Also mice fed a 
diet of medium-chain triglycerides had accumulations of visceral 
fat and liver lipids as well as tissue fat composition changed signif-
icantly.8 Although patients diagnosed by newborn screening have 
greatly reduced mortality associated with all disorders of fatty acid 
oxidation, sudden death has still been reported.30 Having a ther-
apy rather than treatment options could vastly improve patient’s 
quality of life. This work provides proof-of-concept for rAAV9-
mediated gene therapy for VLCAD deficiency.
MAterIAls And Methods
Animals. VLCAD−/− mice were created by Exil et al. and purchased from 
Mutant Mouse Regional Resource Centers (MMRC, University of Missouri, 
Columbia, MO). VLCAD−/− was created by breeding VLCAD–/+ animals cre-
ating VLCAD−/− and VLCAD+/+ littermate controls. Mice were maintained 
in a pathogen-free facility with 12-hour light and dark schedule. Mice were 
fed PicoLab Mouse Diet 20 5058 (LabDiet, Richmond IN) until 2 weeks 
postinjection and then were placed on a standard chow. Mice received both 
diets and water ad libitum. Animals were fasted for 18–24 hours before 
bleeds, magnetic resonance spectrometry or cold fast challenge. For cold 
fast challenge, after the 18-hour fast, mice were singly housed in minimal 
bedding cages and placed in a 4 °C cold room for 150 minutes or until rec-
tal temperatures were below 20 °C. Blood glucose levels were measured by 
Nova Max Glucose Monitor and Strips (Nova Biomedical, Waltham, MA).
All animal procedures were approved by University of Massachusetts 
Medical School Institutional Animal Care and Use Committee as well 
as University of Florida Institutional Animal Care and Use Committee 
in accordance with the Association for Assessment and Accreditation of 
Laboratory Animal Care International specifications.
rAAV vectors. rAAV9/2 pseudotyped vectors were generated to express 
human VLCAD under the transcriptional control of the cytomegalovirus 
enhancer/chicken β-actin promoter.19 rAAV vectors were produced, 
purified and tittered as previously described (UMMS Gene Therapy 
Center, Worcester, MA).31
Genomic DNA extraction and quantitative-PCR. DNA was extracted and 
quantified as previously described.32 Animals were sacrificed at indicated time 
points and tissues were harvested in a manner to avoid cross-contamination, 
snap frozen in liquid nitrogen and stored at −80 °C. gDNA was extracted 
using a DNeasy blood and tissue kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. gDNA concentrations were determined using 
an Eppendorf Biophotometer (Eppendorf, Hamburg, Germany).
rAAV genome copies in the gDNA from heart, liver, tibialis anterior, 
and brown fat were quantified by quantitative-PCR with an ABI 7900 HT 
sequence detection system (Applied Biosystems, Carlsbad, CA) according 
to the manufacturer’s instructions and results were analyzed using SDS 
2.3 software. Briefly, primers and probe were designed to amplify SV40 
poly-A tail of the rAAV9-CBA-VLCAD vector. A standard curve was 
generated using plasmid DNA containing the same SV40 poly-A target 
sequence. PCR contained a total volume of 100 μl and were run at the 
following conditions: 50 °C for 2 minutes, 95 °C for 10 minutes, and 45 
cycles of 95 °C for 15 seconds and 60 °C for 1 minute.
DNA samples were assayed in triplicate. In order to assay PCR 
inhibition, the third replicate was spiked with plasmid DNA at a ratio 
of 100-copies/μg gDNA. If this replicate was greater than 40-copies/μg 
gDNA then the results were considered acceptable. If a sample contained 
greater than or equal to 100-copies/μg gDNA it was considered positive 
for vector genomes. If a sample contained less than 100 copies/μg gDNA 
it was considered negative for vector genomes. If less than 1 μg of gDNA 
was analyzed to avoid PCR inhibition, the vector copy number reported 
was normalized per μg gDNA and the plasmid spike in was reduced to 
maintain the ratio of 100-copies/μg gDNA.
Immunohistochemistry. Tissues were fixed in 10% neutral buffered 
formalin, and embedded in paraffin. Immunohistochemistry was carried 
out by the Molecular Pathology and Immunology Core at University of 
Florida using the DAKO Autostainer plus protocol. Briefly, 4 μm serial 
sections were removed of paraffin and incubated with 3% H2O2 in methanol 
to block endogenous peroxidase activity. Sections were treated with 
Trilogy (Cell Marque, Rocklin, CA) at 95 °C for 25 minutes and blocked 
with Sniper (Biocare Medical, Walnut Creek, CA) to reduce nonspecific 
background staining. Sections were incubated with rabbit anti-mouse 
VLCAD at room temperature for 1 hour. Then sections were incubated 
with Mach2 Gt × Rb HRP polymer (Biocare Medical) for 30 minutes. 
Staining was visualized with DAB chromagen (Biocare Medical).
Mass spectrometry. Blood acyl carnitines were extracted, derivatized, 
and analyzed as described previously.33 The following labeled carnitine 
standards (Cambridge Isotope Laboratories, Andover, MA) were used for 
quantification: l-Carnitine (N-trimethyl-D9), l-acetylcarnitine (N-methyl-
D3), l-propionylcarnitine (N-methyl-D3), l-butyrylcarnitine (N-methyl-D3), 
l-isovalerylcarnitine (N-trimethyl-D9), l-octanoylcarnitine (N-methyl-
D3), l-myristoylcarnitine (N-trimethyl-D9) and l-palmitoyl carnitine (N-
methyl-D3). Blood acyl carnitine samples were analyzed as butyl esters on 
a Micromass Quattro II (Manchester, UK) with an electrospray ionization 
source operating in the positive ion mode by direct infusion. Tissue samples 
were processed as previously described.34 In brief, frozen tissue samples 
were ground into powder and resuspended in 80% acetonitrile containing 
carnitine standards described above at a concentration of 60 mg/ml. Samples 
were homogenized and centrifuged, supernatants were dried under nitrogen. 
Samples were then resuspended in 10% acetyl chloride in 1-butanol and 
heated at 65 °C for 15 minutes, dried under nitrogen and brought up in 80% 
acetonitrile for analysis. Samples were run in triplicate on a Waters (Milford, 
MA) Premier XE triple quadrupole mass spectrometer similarly to the blood 
samples.
1H-MRS. Single voxel 1H-MRS was obtained from the tibialis anterior 
muscle and liver at 11.1T and 4.7T, respectively. 11.1T localized proton 
muscle spectra were obtained using a Bruker spectrometer (PV3) as 
described previously.9 A custom-made loop gap coil with 1.4-cm inner 
diameter tuned to 470.5 MHz was used. Localizer anatomical proton 
magnetic resonance images were acquired using FLASH (matrix, 256 
× 256; echo time = 4.3 msec; repetition time = 207 msec, FOV = 20 × 
20 mm2) were acquired in three orthogonal directions for the precise 
localization of a volume of interest from which proton MRS would be 
obtained. Water suppression was optimized by chemical shift-selective 
water suppression. Localized spectra were acquired by point-resolved 
spatially localized spectroscopy (echo time = 18 msec; repetition time = 
3,000 msec; number of excitations = 512, bandwidth = 8,013 Hz, number 
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of complex points = 2,048). Data were processed using jMRUI (http://
www.mrui.uab.es/mrui/mrui_Overview.shtml). Similarly localized single 
voxel proton liver spectra were obtained at 4.7T using point-resolved 
spatially localized spectroscopy (echo time = 14 msec; repetition time = 
2,500 msec; number of excitations = 16, bandwidth = 3,005 Hz, number 
of complex points = 8,196) on a Varian/Agilent spectrometer. Liver MRS 
was processed using in house software (IDL; ITT) in order to determine 
the integral of water and lipid resonances.
Statistics. All statistics were carried out using Prism 5 Software (GraphPad 
Software, San Diego, CA). All data are presented as means ± SEM. The 
n value designates number of animals used. Significant differences were 
determined by unpaired Student’s t-test. When looking at the effect of two 
variables, such as reduction of acyl carnitines and time, or temperature and 
time, a two-way analysis of variance were used to determine significance. 
Differences were considered significant if P < 0.05.
suPPleMentArY MAterIAl
Figure S1. Inflammation of liver postinjection.
Figure S2. Reduction of acyl carnitines in rAAV9-VLCAD with GFP 
control.
Figure S3. Acyl carnitine profiles over time in uninjected mice.
Video S1. Representative video of VLCAD−/− PBS control mouse after 
18-hour fast and 120 minutes at 4 °C.
Video S2. Representative video of VLCAD−/− AAV9-treated mouse af-
ter 18-hour fast and 150 minutes at 4 °C.
Video S3. Representative video of VLCAD+/+ PBS control mouse after 
18-hour fast and 150 minutes at 4°C.
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